Status:
COMPLETED
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
Lead Sponsor:
Bayer
Conditions:
Hemophilia A
Eligibility:
All Genders
Brief Summary
In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol. Patients enrolled in this study will be wearing a small d...
Detailed Description
The primary objective is to evaluate the change in physical non-sedentary activity as measured by the ActiGraph CentrePoint Insight Watch (ActiGraph LLC, Pensacola, Florida) after 1, 2 and 3 years of ...
Eligibility Criteria
Inclusion
- Enrolled in the HEM-POWR study (NCT03932201)
- Naïve to damoctocog alfa pegol prior to enrollment to HEM-POWR study
- Prescribed for prophylaxis treatment for hemophilia with damoctocog alfa pegol
- Patient is willing to wear the provided device
- Signed informed consent/assent to participate in LIFE-ACTIVE: Observational study evaluating the physical activity in a subset of damoctocog alfa pegol treated Hemophilia A patients who are enrolled in the HEM-POWR study
Exclusion
- Hypersensitivity to any material of activity monitor (e.g. steel, rubber)
- Time gap between enrollment to HEM-POWR study and enrollment to LIFE-ACTIVE study is greater than 6 months
Key Trial Info
Start Date :
June 10 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 5 2024
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04091386
Start Date
June 10 2021
End Date
July 5 2024
Last Update
June 15 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Center for Comprehensive Care and Diagnosis of Inherited Blood Disorders
Orange, California, United States, 92868
2
Tulane University
New Orleans, Louisiana, United States, 70118
3
Many Locations
Multiple Locations, Belgium
4
Many Locations
Multiple Locations, Canada